Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Neurosci ; 32(21): 7392-402, 2012 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-22623685

RESUMEN

Glycogen synthase kinase-3 (GSK-3) is linked to the pathogenesis of Alzheimer's disease (AD), senile plaques (SPs), and neurofibrillary tangles (NFTs), but the specific contributions of each of the GSK-3 α and ß isoforms to mechanisms of AD have not been clarified. In this study, we sought to elucidate the role of each GSK-3α and GSK-3ß using novel viral and genetic approaches. First, we developed recombinant adeno-associated virus 2/1 short hairpin RNA constructs which specifically reduced expression and activity of GSK-3α or GSK-3ß. These constructs were injected intraventricularly in newborn AD transgenic (tg) mouse models of SPs (PDAPP⁺/⁻), both SPs and NFTs (PDAPP⁺/⁻;PS19⁺/⁻), or wild-type controls. We found that knockdown (KD) of GSK-3α, but not GSK-3ß, reduced SP formation in PDAPP⁺/⁻ and PS19⁺/⁻;PDAPP⁺/⁻ tg mice. Moreover, both GSK-3α and GSK-3ß KD reduced tau phosphorylation and tau misfolding in PS19⁺/⁻;PDAPP⁺/⁻ mice. Next, we generated triple tg mice using the CaMKIIα-Cre (α-calcium/calmodulin-dependent protein kinase II-Cre) system to KD GSK-3α in PDAPP⁺/⁻ mice for further study of the effects of GSK-3α reduction on SP formation. GSK-3α KD showed a significant effect on reducing SPs and ameliorating memory deficits in PDAPP⁺/⁻ mice. Together, the data from both approaches suggest that GSK-3α contributes to both SP and NFT pathogenesis while GSK-3ß only modulates NFT formation, suggesting common but also different targets for both isoforms. These findings highlight the potential importance of GSK-3α as a possible therapeutic target for ameliorating behavioral impairments linked to AD SPs and NFTs.


Asunto(s)
Enfermedad de Alzheimer/patología , Terapia Genética/psicología , Glucógeno Sintasa Quinasa 3/biosíntesis , Glucógeno Sintasa Quinasa 3/fisiología , Ovillos Neurofibrilares/metabolismo , Placa Amiloide/metabolismo , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Animales , Encéfalo/metabolismo , Encéfalo/patología , Modelos Animales de Enfermedad , Femenino , Técnicas de Silenciamiento del Gen/métodos , Terapia Genética/métodos , Glucógeno Sintasa Quinasa 3 beta , Masculino , Trastornos de la Memoria/genética , Trastornos de la Memoria/terapia , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Transducción de Señal/genética , Transducción de Señal/fisiología , Proteínas tau/metabolismo
2.
Nat Commun ; 2: 252, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21427723

RESUMEN

The microtubule associated protein tau promotes neuronal survival through binding and stabilization of MTs. Phosphorylation regulates tau-microtubule interactions and hyperphosphorylation contributes to the aberrant formation of insoluble tau aggregates in Alzheimer's disease (AD) and related tauopathies. However, other pathogenic post-translational tau modifications have not been well characterized. Here we demonstrate that tau acetylation inhibits tau function via impaired tau-microtubule interactions and promotes pathological tau aggregation. Mass spectrometry analysis identified specific lysine residues, including lysine 280 (K280) within the microtubule-binding motif as the major sites of tau acetylation. Immunohistochemical and biochemical studies of brains from tau transgenic mice and patients with AD and related tauopathies showed that acetylated tau pathology is specifically associated with insoluble, Thioflavin-positive tau aggregates. Thus, tau K280 acetylation in our studies was only detected in diseased tissue, suggesting it may have a role in pathological tau transformation. This study suggests that tau K280 acetylation is a potential target for drug discovery and biomarker development for AD and related tauopathies.


Asunto(s)
Lisina/análisis , Proteínas de la Membrana/metabolismo , Microtúbulos/metabolismo , Neuronas/metabolismo , Proteínas Recombinantes/metabolismo , Acetilación , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Animales , Encéfalo/metabolismo , Encéfalo/patología , Femenino , Células HEK293 , Humanos , Inmunohistoquímica , Lisina/genética , Lisina/metabolismo , Masculino , Espectrometría de Masas , Proteínas de la Membrana/genética , Ratones , Ratones Transgénicos , Microtomía , Microtúbulos/patología , Persona de Mediana Edad , Neuronas/patología , Fosforilación , Unión Proteica , Procesamiento Proteico-Postraduccional , Proteínas Recombinantes/genética , Transfección
3.
Am J Pathol ; 177(4): 1977-88, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20802182

RESUMEN

Senile plaques formed by ß-amyloid peptides (Aß) and neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau, a microtubule-associated protein, are the hallmark lesions of Alzheimer's disease (AD) in addition to loss of neurons. While several transgenic (Tg) mouse models have recapitulated aspects of AD-like Aß and tau pathologies, a spatiotemporal mapping paradigm for progressive NFT accumulation is urgently needed to stage disease progression in AD mouse models. Braak and co-workers developed an effective and widely used NFT staging paradigm for human AD brains. The creation of a Braak-like spatiotemporal staging scheme for tau pathology in mouse models would facilitate mechanistic studies of AD-like tau pathology. Such a scheme would also enhance the reproducibility of preclinical AD therapeutic studies. Thus, we developed a novel murine model of Aß and tau pathologies and devised a spatiotemporal scheme to stage the emergence and accumulation of NFTs with advancing age. Notably, the development of NFTs followed a spatiotemporal Braak-like pattern similar to that observed in authentic AD. More significantly, the presence of Aß accelerated NFT formation and enhanced tau amyloidosis; however, tau pathology did not have the same effect on Aß pathology. This novel NFT staging scheme provides new insights into the mechanisms of tau pathobiology, and we speculate that this scheme will prove useful for other basic and translational studies of AD mouse models.


Asunto(s)
Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/metabolismo , Amiloidosis/etiología , Encéfalo/patología , Ovillos Neurofibrilares/patología , Neuronas/patología , Proteínas tau/metabolismo , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/genética , Amiloidosis/metabolismo , Amiloidosis/patología , Animales , Peso Corporal , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Humanos , Técnicas para Inmunoenzimas , Ratones , Ratones Transgénicos , Ovillos Neurofibrilares/metabolismo , Neuronas/metabolismo , Fenotipo , Placa Amiloide/metabolismo , Placa Amiloide/patología , Tasa de Supervivencia
4.
Biochem Biophys Res Commun ; 310(1): 8-13, 2003 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-14511640

RESUMEN

Kainate receptors are a class of ionotropic glutamate receptors that are widely expressed in the mammalian brain, yet little is known about their physiological role or the mechanisms by which they are regulated. Kainate receptors are composed of multiple subunits (GluR5-7; KA1-2), which can combine to form homomeric or heteromeric channels. While the kainate receptor subunit KA2 can combine with GluR5-7 to form heteromeric channels, it does not form functional homomeric channels when expressed alone. In an attempt to identify the molecular mechanisms for this, we have characterized the trafficking and surface expression of KA2. We find that KA2 alone does not traffic to the plasma membrane and is retained in the endoplasmic reticulum (ER). In contrast, co-expression with GluR6 disrupts ER-retention of KA2 and allows plasma membrane expression. Using a chimeric reporter protein we have identified an ER-retention motif within the KA2 cytosolic domain. Recent studies have identified a consensus ER-retention motif (RRR) that is contained within both the NMDA receptor NR1 subunit and K(+) channels. While KA2 contains a similar stretch of amino acids within its C-terminus (RRRRR), unlike the NR1 motif, disruption of this motif with alternating glutamic acid residues does not disrupt ER-retention of KA2, suggesting a unique mechanism regulating KA2 surface expression.


Asunto(s)
Receptores de Glutamato/metabolismo , Retículo Endoplásmico/metabolismo , Células HeLa , Humanos , Transporte de Proteínas , Receptores de Glutamato/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA